AML’s growing options
A side-by-side look at new AML therapies
For acute myelogenous leukemia patients, 2017 marked the end of a more than 40 year drought in which chemotherapy was the only treatment option. In the last three years, eight new AML therapies have come to market spanning newly diagnosed and relapsed or refractory settings, and most target molecularly-defined patient subgroups.
Three of the newly approved agents target FLT3-mutated AML, and